Similar articles

• Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.

  Brazzelli V, Roveda E, Prestinari F, Barbagallo T, Bellani E, Trevisan V, Rona C, Locatelli F, Zecca M, Borroni G. Brazzelli V, et al. Pediatr Dermatol. 2006 Mar-Apr;23(2):175-8. doi: 10.1111/j.1525-1470.2006.00208.x. Pediatr Dermatol. 2006. PMID: 16650231
• PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.

  Guru SA, Mir R, Bhat M, Najar I, Zuberi M, Sumi M, Masroor M, Gupta N, Saxena A. Guru SA, et al. Tumour Biol. 2017 Oct;39(10):1010428317713857. doi: 10.1177/1010428317713857. Tumour Biol. 2017. PMID: 29019285
• Hypertrophic osteoarthropathy with imatinib therapy.

  Cundy T, Porter D, Grey A. Cundy T, et al. Intern Med J. 2015 Oct;45(10):1088-90. doi: 10.1111/imj.12858. Intern Med J. 2015. PMID: 26429221 No abstract available.
• Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.

  Oliveira SR, de Azevedo Branco LG, Rocha AL, Travassos DV, Magalhães GHR, Fonseca FP, Mesquita RA, Abreu LG, da Silva TA. Oliveira SR, et al. Clin Oral Investig. 2019 Dec;23(12):4371-4382. doi: 10.1007/s00784-019-02886-0. Epub 2019 Apr 9. Clin Oral Investig. 2019. PMID: 30968242
• Imatinib mesylate-induced lichenoid drug eruption.

  Penn EH, Chung HJ, Keller M. Penn EH, et al. Cutis. 2017 Mar;99(3):189-192. Cutis. 2017. PMID: 28398413 Review.